Success Metrics

Clinical Success Rate
81.3%

Based on 39 completed trials

Completion Rate
81%(39/48)
Active Trials
7(11%)
Results Posted
54%(21 trials)
Terminated
9(15%)

Phase Distribution

Ph phase_1
9
15%
Ph phase_2
29
48%
Ph phase_3
7
11%
Ph not_applicable
4
7%
Ph phase_4
6
10%
Ph early_phase_1
4
7%

Phase Distribution

13

Early Stage

29

Mid Stage

13

Late Stage

Phase Distribution59 total trials
Early Phase 1First-in-human
4(6.8%)
Phase 1Safety & dosage
9(15.3%)
Phase 2Efficacy & side effects
29(49.2%)
Phase 3Large-scale testing
7(11.9%)
Phase 4Post-market surveillance
6(10.2%)
N/ANon-phased studies
4(6.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

79.6%

39 of 49 finished

Non-Completion Rate

20.4%

10 ended early

Currently Active

7

trials recruiting

Total Trials

61

all time

Status Distribution
Active(7)
Completed(39)
Terminated(10)
Other(5)

Detailed Status

Completed39
Terminated9
Recruiting6
unknown4
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
61
Active
7
Success Rate
81.3%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (6.8%)
Phase 19 (15.3%)
Phase 229 (49.2%)
Phase 37 (11.9%)
Phase 46 (10.2%)
N/A4 (6.8%)

Trials by Status

terminated915%
unknown47%
withdrawn12%
active_not_recruiting12%
suspended12%
recruiting610%
completed3964%

Recent Activity

Clinical Trials (61)

Showing 20 of 61 trialsScroll for more
NCT06580002Phase 2

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial

Recruiting
NCT03722680Phase 2

Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.

Suspended
NCT04745299Phase 3

Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS

Completed
NCT01303341Phase 1

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

Active Not Recruiting
NCT07447050Phase 2

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial

Recruiting
NCT07414212Phase 1

Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)

Recruiting
NCT03039673Phase 2

MIROCALS: Modifying Immune Response and OutComes in ALS

Completed
NCT03127267Phase 3

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

Recruiting
NCT01661855Phase 2

A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD

Completed
NCT04761614Phase 1

Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Completed
NCT00202397Phase 2

Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia

Completed
NCT03660917Phase 2

Riluzole in Patients With Spinocerebellar Ataxia Type 7

Recruiting
NCT06676423Phase 1

Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS

Completed
NCT06270108Early Phase 1

The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia

Recruiting
NCT00866840Phase 2

Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Completed
NCT02588677Phase 2

Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Completed
NCT02859792Phase 2

Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition

Unknown
NCT02238626Phase 2

Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Completed
NCT01703117Phase 2

Riluzole in Mild Alzheimer's Disease

Completed
NCT03347344Phase 3

Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
61